BACKGROUND: To provide optimal treatment of heterogeneous triple negative breast cancer (TNBC), we need biomarkers that can predict the chemotherapy response. PATIENTS AND METHODS: We retrospectively investigated BRCAness in 73 patients with breast cancer who had been treated with taxane- and/or anthracycline-based neoadjuvant chemotherapy (NAC). Using multiplex, ligation-dependent probe amplification on formalin-fixed core needle biopsy (CNB) specimens before NAC and surgical specimens after NAC. BRCAness status was assessed with the assessor unaware of the clinical information. RESULTS: We obtained 45 CNB and 60 surgical specimens from the 73 patients. Of the 45 CNB specimens, 17 had BRCAness (38.6% of all subtypes). Of the 23 TNBC CNB specimens, 14 had BRCAness (61% of TNBC cases). The clinical response rates were significantly lower for BRCAness than for non-BRCAness tumors, both for all tumors (58.8% vs. 89.3%, P = .03) and for TNBC (50% vs. 100%, P = .02). All tumors that progressed with taxane therapy had BRCAness. Of the patients with TNBC, those with non-BRCAness cancer had pathologic complete responses significantly more often than did those with BRCAness tumors (77.8% vs. 14.3%, P = .007). After NAC, the clinical response rates were significant lower for BRCAness than for non-BRCAness tumors in all subtypes (P = .002) and in TNBC cases (P = .008). After a median follow-up of 26.4 months, 6 patients-all with BRCAness-had developed recurrence. Patients with BRCAness had shorter progression-free survival than did those with non- BRCAness (P = .049). CONCLUSION: Identifying BRCAness can help predict the response to taxane, and changing regimens for BRCAness TNBC might improve patient survival. A larger prospective study is needed to further clarify this issue.
BACKGROUND: To provide optimal treatment of heterogeneous triple negative breast cancer (TNBC), we need biomarkers that can predict the chemotherapy response. PATIENTS AND METHODS: We retrospectively investigated BRCAness in 73 patients with breast cancer who had been treated with taxane- and/or anthracycline-based neoadjuvant chemotherapy (NAC). Using multiplex, ligation-dependent probe amplification on formalin-fixed core needle biopsy (CNB) specimens before NAC and surgical specimens after NAC. BRCAness status was assessed with the assessor unaware of the clinical information. RESULTS: We obtained 45 CNB and 60 surgical specimens from the 73 patients. Of the 45 CNB specimens, 17 had BRCAness (38.6% of all subtypes). Of the 23 TNBC CNB specimens, 14 had BRCAness (61% of TNBC cases). The clinical response rates were significantly lower for BRCAness than for non-BRCAness tumors, both for all tumors (58.8% vs. 89.3%, P = .03) and for TNBC (50% vs. 100%, P = .02). All tumors that progressed with taxane therapy had BRCAness. Of the patients with TNBC, those with non-BRCAness cancer had pathologic complete responses significantly more often than did those with BRCAness tumors (77.8% vs. 14.3%, P = .007). After NAC, the clinical response rates were significant lower for BRCAness than for non-BRCAness tumors in all subtypes (P = .002) and in TNBC cases (P = .008). After a median follow-up of 26.4 months, 6 patients-all with BRCAness-had developed recurrence. Patients with BRCAness had shorter progression-free survival than did those with non- BRCAness (P = .049). CONCLUSION: Identifying BRCAness can help predict the response to taxane, and changing regimens for BRCAness TNBC might improve patient survival. A larger prospective study is needed to further clarify this issue.
Authors: Rosa Murria Estal; Sarai Palanca Suela; Inmaculada de Juan Jiménez; Cristina Alenda Gonzalez; Cecilia Egoavil Rojas; Zaida García-Casado; Jose Antonio López Guerrero; María José Juan Fita; Ana Beatriz Sánchez Heras; Ángel Segura Huerta; Ana Santaballa Bertrán; Isabel Chirivella González; Marta Llop García; Gema Pérez Simó; Eva Barragán González; Pascual Bolufer Gilabert Journal: Fam Cancer Date: 2016-04 Impact factor: 2.375
Authors: Annelot G J van Rossum; Ingrid A M Mandjes; Erik van Werkhoven; Harm van Tinteren; A Elise van Leeuwen-Stok; Petra Nederlof; Johanna E A Portielje; Robbert J van Alphen; Els Platte; Daan van den Broek; Alwin Huitema; Marleen Kok; Sabine C Linn; Hendrika M Oosterkamp Journal: Breast Care (Basel) Date: 2021-01-22 Impact factor: 2.860
Authors: Xuan Liu; Zhongqi Ge; Fei Yang; Alejandro Contreras; Sanghoon Lee; Jason B White; Yiling Lu; Marilyne Labrie; Banu K Arun; Stacy L Moulder; Gordon B Mills; Helen Piwnica-Worms; Jennifer K Litton; Jeffrey T Chang Journal: NPJ Breast Cancer Date: 2022-05-10
Authors: Dominik Glodzik; Ana Bosch; Serena Nik-Zainal; Åke Borg; Johan Staaf; Johan Hartman; Mattias Aine; Johan Vallon-Christersson; Christel Reuterswärd; Anna Karlsson; Shamik Mitra; Emma Niméus; Karolina Holm; Jari Häkkinen; Cecilia Hegardt; Lao H Saal; Christer Larsson; Martin Malmberg; Lisa Rydén; Anna Ehinger; Niklas Loman; Anders Kvist; Hans Ehrencrona Journal: Nat Commun Date: 2020-07-27 Impact factor: 14.919